Invention Grant
- Patent Title: Use of Eomesodermin to determine risk of allograft rejection
-
Application No.: US15545414Application Date: 2016-01-22
-
Publication No.: US11022601B2Publication Date: 2021-06-01
- Inventor: Mohamed B. Ezzelarab , Angus W. Thomson
- Applicant: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicant Address: US PA Pittsburgh
- Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Current Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Current Assignee Address: US PA Pittsburgh
- Agency: Klarquist Sparkman, LLP
- International Application: PCT/US2016/014507 WO 20160122
- International Announcement: WO2016/118852 WO 20160728
- Main IPC: G01N33/50
- IPC: G01N33/50
Abstract:
Pre-existing alloreactive memory T cells are a major barrier to the induction of allograft tolerance in organ transplant recipients. The use of Eomesodermin (Eomes) expression in memory T cells to determine the risk of allograft rejection in a subject is described. Also described is the use of Eomes expression in memory T cells of transplant recipients to modify immunosuppressive therapy.
Public/Granted literature
- US20180045710A1 USE OF EOMESODERMIN TO DETERMINE RISK OF ALLOGRAFT REJECTION Public/Granted day:2018-02-15
Information query
IPC分类:
